Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Increase in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 808,600 shares, an increase of 42.5% from the February 28th total of 567,600 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 979,300 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Tiziana Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new position in shares of Tiziana Life Sciences during the third quarter worth $864,000. Geode Capital Management LLC boosted its position in Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock valued at $171,000 after purchasing an additional 27,041 shares during the period. Zhang Financial LLC grew its position in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after acquiring an additional 23,800 shares during the last quarter. Finally, Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the 4th quarter valued at $30,000.

Tiziana Life Sciences Stock Performance

NASDAQ:TLSA traded down $0.04 during mid-day trading on Monday, hitting $1.09. 95,608 shares of the company’s stock traded hands, compared to its average volume of 450,450. Tiziana Life Sciences has a 1 year low of $0.41 and a 1 year high of $1.91. The firm’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $0.94.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.